share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Apr 16 04:29
Summary by Futu AI
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.